Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 414 participants.
Also called NCT01703221
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 414 participants
- Sponsor
- Registry
-
NCT01703221
-
- Main results
- A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01703221. Randomized; triple masking; primary purpose treatment. Start 2012-10-24 (actual); primary completion 2014-04-25 (actual). Results posted on 2015-10-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo to omarigliptin
- Intervention (Drug)
- Placebo to sitagliptin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01703221- Content hash
af19ad26396fcb31c1afe218d46f38bf0d2344ba332a28ffe9f6e04ecb5208e4